Nano‑X has multiple regulatory clearances—including an FDA clearance for “general apply” (Dec 2024) and a recent “tomo 2D” clearance, plus CE approval in early 2025—and states U.S. commercialization launched in 2023 with European commercialization planned for 2025 and distribution deals in the Czech Republic, France and Slovakia.
The company’s flagship systems, the Nanox.ARC and FDA‑cleared ARC X, apply a cold cathode MEMS multi‑source design (five tubes) to deliver a compact, plug‑and‑play tomosynthesis workflow—about a 12‑second sweep producing 30–60 2D images that are cloud‑reconstructed into 3D images and support remote monitoring and PACS integration.
Nano‑X sells via outright purchase or a pay‑per‑apply $30 per scan model; with an estimated reimbursement code range of ~$88–$109, the company projects operator net margins of roughly 48%–62% under pay‑per‑apply, and it also markets FDA/CE‑approved AI tools for chest, spine and liver analysis to health systems and B2B2C partners.
Nano-X Imaging (NASDAQ:NNOX) Chief Financial Officer Daniel provided an overview of the company’s imaging platform, commercialization approach, and recent regulatory and business developments during a presentation aimed at existing and prospective investors.
Daniel described Nano-X as an imaging company focapplyd on an “finish-to-finish solution from scan to diagnosis.” He declared the company’s platform includes the Nanox.ARC imaging system as a central component, alongside teleradiology and an artificial innotifyigence and software division that was recently expanded through the acquisition of VasoHealthcare IT, now referred to as Nanox Health IT.
According to Daniel, the Nanox.ARC is a digital multi-source 3D tomosynthesis imaging system. He declared the company has multiple U.S. Food and Drug Administration (FDA) clearances and has also received CE approval to market devices in Europe.
Daniel declared the company launched commercialization of the Nanox.ARC in the U.S. in 2023 and expects to launch commercialization in Europe during 2025. In the U.S., he declared Nano-X applys both direct and indirect sales models, while outside the U.S. it works through distributors.
On the regulatory side, Daniel highlighted that the company received an FDA clearance in December 2024 for “general apply,” and more recently obtained clearance for “tomo 2D” software, which he declared allows the company to sell both 3D and 2D solutions from the Arc platform. He also referenced CE approval obtained in early 2025.
He added that Nano-X has signed distribution agreements in Europe, citing the Czech Republic and France, and declared the company had also announced an agreement involving Slovakia, with additional agreements potentially forthcoming.
Daniel traced the company’s core technology to a silicon-based, low-voltage, nanoscale cold cathode chip designed to generate the electron stream requireded for X-rays applying field emission technology. He declared the technology originated from work initially developed at Sony during the era of “thin TV” development, later spun out with a group of scientists to the University of Tokyo, where Nano-X founder Ran Poliakine became involved.
He contrasted Nano-X’s cold cathode approach with conventional X-ray systems that apply a heated metal filament, noting that legacy systems require high temperatures and cooling cycles. He declared Nano-X’s approach eliminates some of those mechanical and cooling requirements and can offer cost advantages.
Daniel declared each ARC system applys five tubes, with one chip per tube. He also discussed tube development, describing a first-generation ceramic tube developed by the company’s subsidiary in Korea and a second-generation glass tube planned for newer device generations.
Daniel described the first-generation ARC as a compact, lightweight, multi-source tomosynthesis system, and declared the second-generation ARC X is compacter and lighter, with system components integrated into the device rather than requiring an external electrical cabinet connection. He declared the ARC X has already been cleared by the FDA and was presented at the most recent RSNA meeting, and that commercialization of ARC X devices is launchning in the U.S.
He outlined operational characteristics of the system, including low power requirements and a “plug and play” setup for the new generation, as well as quick installation and training. He described a scan workflow in which a patient is positioned on a bed, settings are programmed via an iPad, and the system performs a tomographic sweep, tilting about 15–18 degrees to each side. He declared the scan process takes no more than 12 seconds and generates 30–60 2D images, which are sent to the cloud and reconstructed via proprietary software into a 3D image.
Daniel also declared the platform supports remote monitoring and updates and can integrate with PACS systems. He noted that through Nanox Health IT, the company can resell PACS software from medQ, RamSoft, Ambra, and Candelis, while emphasizing that Nano-X does not force customers to acquire an finish-to-finish package.
Daniel declared Nano-X is tarobtaining imaging centers, urgent care locations, orthopedic clinics, and multipurpose specialty clinics in the U.S., describing these as “blue ocean” markets where the company aims to avoid competing directly with larger incumbents.
He outlined two customer models:
Outright purchase, sometimes supported by financing arranged for customers.
Medical scan-as-a-service (pay-per-apply), which he declared is priced at $30 per scan, typically structured as a multiyear contract.
In discussing scan economics, Daniel cited a reimbursement code of 76100 with a range he described as approximately $88–$109 per procedure. He declared that under the pay-per-apply model, operators can generate a net margin of 48%–62% after paying $30 per scan, and that reading services can provide a margin of about 33% when operators receive $30 and pay Nano-X $20 for the professional component. He added that pay-per-apply rates are lower outside the U.S. but declared they remain attractive economically for the company.
On AI, Daniel declared Nano-X’s tools are FDA- and CE-approved and are intfinished to assist physicians identify asymptomatic chronic disease earlier to support preventive management. He declared the AI portfolio is built around chest-related coronary artery calcium scoring, a spinal measurement solution (including vertebral compression and wedge loss indications), and liver-related analysis including fatty liver. He declared the company has health system customers for its AI products, citing Spectrum Health in the Northeast as the largest and noting it is in its fifth year of engagement. He also referenced a B2B2C model introduced in 2025, giving Ezra as an example customer applying Nano-X’s AI solutions for chest and bone-related scans.
In brief comments on the company’s OEM business, Daniel declared the company is pursuing licensing and royalty opportunities based on its technology and IP, and mentioned a recent project with a “semi-government agency” related to security that is testing the company’s chip and tube.
During Q&A, Daniel declared he could not provide details on the number of ARC systems deployed due to a blackout period and directed investors to wait for the next earnings call. He also declared there had been no disruption to development or production of the ARC related to the war in Israel “as of today.” Regarding the Oak Ridge question, he declared the organization was testing Nano-X’s tube and chip as part of a multi-stage project, while noting Nano-X had limited information beyond public statements.
Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.
The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the required for rotating anode tubes.
Leave a Reply